复星医药芦沃美替尼片注册申请获受理

Core Viewpoint - Fosun Pharma's subsidiary has received acceptance for a drug registration application for Rumaine (generic name: Lenvatinib) to treat children aged 2 and above with Langerhans Cell Histiocytosis (LCH), which has been included in the priority review process by the National Medical Products Administration [1] Group 1: Drug Information - Rumaine is a selective MEK1/2 inhibitor [1] - The drug has already been approved for two indications in China: treatment of LCH in adult patients and treatment of symptomatic, inoperable plexiform neurofibromas (PN) in children and adolescents aged 2 and above with Neurofibromatosis Type 1 (NF1) [1]